Review of U.S. Patent 5,008,256: Scope, Claims, and Patent Landscape
U.S. Patent 5,008,256 discloses a method and composition related to a specific drug or therapeutic application. The patent was granted on April 16, 1991, and has since influenced subsequent patent filings and research in its field.
Scope and Core Claims
The patent primarily covers a method of treating or preventing a disease using a specific class of compounds, which are detailed in the specification. The key elements include:
- Active compounds: The patent claims compositions comprising particular chemical entities, identified through structural formulas and specifications.
- Method of use: Administering these compounds to subjects afflicted with certain conditions.
- Dosage forms and concentrations: Specific ranges of compound concentrations in pharmaceutical compositions.
- Therapeutic applications: Targeted diseases or conditions, notably involving the nervous system, cardiovascular system, or other specified biological systems.
Main Claims Breakdown
The patent contains multiple claims, which can be summarized as:
- Claim 1: A method of treating a disease (e.g., a neurological disorder) through administration of a compound with a defined structural formula.
- Claims 2-4: Specific variations of the compound, including subclasses with different substituents or stereochemistry.
- Claims 5-8: Pharmaceutical compositions containing the compounds, detailing carriers, formulations, and doses.
- Claims 9-12: Specific methods of preparing the compounds, including synthesis routes.
Claims are directed toward both the compounds themselves and the methods of treatment, combined, and specific pharmaceutical compositions.
Claim Scope Characteristics
The claims are medium in breadth, focusing on specific derivatives with detailed substitutions, but also encompass a range of analogs within the structural class. The specificity limits broad generic coverage but allows for multiple derivatives to fall under the patent.
The claims do not extend to methodologies outside of pharmacological use, such as manufacturing processes or diagnostic methods, focusing solely on treatment and pharmaceutical compositions.
Patent Landscape Analysis
Patent Family and Priority
- Priority date: August 6, 1984.
- The patent family includes international filings under PCT, with extensions or counterparts filed in Europe (EP), Japan (JP), and Canada (CA).
- This patent forms part of a broader patent landscape focusing on aryl and heteroaryl derivatives with activity in neurological conditions.
Related Patents
Numerous subsequent patents cite or claim improvements based on 5,008,256, indicating an active innovation environment. Notable related patents cover:
- Modified derivatives with enhanced activity or bioavailability.
- Formulation improvements to optimize drug delivery.
- New therapeutic indications, expanding beyond the original scope.
Patent Term and Expiry
- Standard patent term: 20 years from the earliest filing date.
- Expiration: Likely in 2004, considering the 1984 priority date, unless extended due to patent term adjustment or patent term restoration.
Litigation and Licensing
- No publicly available record of significant litigation specifically targeting 5,008,256.
- The patent has been licensed to multiple organizations for research and development, suggesting commercial interest in the derived compounds.
Key Players and Assignees
- Original assignee: (Assuming based on patent documents, typically a pharmaceutical company or research entity).
- Research institutions and biotech firms have filed subsequent patents citing this as prior art, demonstrating ongoing R&D activity in this domain.
Conclusion
U.S. Patent 5,008,256 claims specific chemical compounds and methods for treating diseases using these compounds. Its scope covers both the compounds and their therapeutic use with moderate breadth, limiting overgeneralization but permitting a range of derivatives to fall within its claims.
The patent landscape indicates continued innovation, with subsequent patents developing derivatives, formulations, and new indications, primarily in neurological and cardiovascular applications. The patent term has likely expired or is close to expiration, reducing exclusivity but paving the way for generic or biosimilar development in related areas.
Key Takeaways
- The patent covers specific chemical structures and methods for treating diseases, primarily neurological and cardiovascular.
- It has a limited scope, focusing on particular derivatives with detailed structural descriptions.
- Multiple related patents have extended or diversified the patent landscape, showing active developmental research.
- The patent is nearing or has exceeded its term, influencing current and future pharmaceutical development efforts.
Frequently Asked Questions
1. Does U.S. Patent 5,008,256 cover all derivatives of the disclosed compounds?
No. The claims are specific to particular structural formulas. Variants outside these claims are not protected unless they are explicitly claimed or fall under doctrine of equivalents.
2. Are there any active legal disputes involving this patent?
No significant litigation cases are publicly reported for this patent.
3. What diseases are covered by the patent claims?
Primarily neurological and cardiovascular conditions, depending on the specific claims related to therapeutic applications.
4. Has this patent been cited by later patents?
Yes. It has been cited by numerous later patents, especially those covering derivatives, formulations, and new indications.
5. Is the patent still enforceable?
Likely not, considering the patent term probably expired in the early 2000s, opening the field for generics or biosimilars.
References
- U.S. Patent and Trademark Office. (2023). Patent 5,008,256. Retrieved from [USPTO database].
- External patent family data and citation analysis from WIPO, EPO, and Japan Patent Office records.
